Judie Brown, president of American Life League, issued the following statement regarding the Food and Drug Administration’s current review of Barr Laboratories’ request to make the dangerous drug available over the counter for anyone over 16:
Plan-B is a risky drug regimen that can take the life of a newly conceived baby. The federal government should never sanction abortion in any form, whether the means of death are chemical or surgical. This so-called emergency contraception should have never been approved by the FDA in the first place and should certainly not be made readily available over-the-counter.
The FDA has already denied Barr Laboratories’ request for over-the-counter approval of this drug once, and hopefully will make the same decision again. The latest application submitted by Barr Laboratories in July 2004 requests that the drug be made available over-the counter for anyone over the age of 16, and by prescription to any girl under 16. However, this is a ridiculous scenario that will be near impossible to enforce. Groups such as Planned Parenthood have proven time and again that they are willing to bend the rules when it comes to abortion and contraception, and they will surely do the same with Plan B.
There is a colossal lack of pertinent information about this drug. There are no studies indicating the long-term side effects of these pills when used by adolescents, nor are there studies to help us understand what will happen to a young woman who relies solely on the mega-doses these pills dump into her system each time she takes the pills. The one thing we know for sure is that this deadly drug can and will cause the death of a preborn baby.
If the FDA truly cares about the health and well-being of women, it would act to remove this dangerous drug from the market altogether. The FDA is expected make a decision on the over-the-counter status of Plan B by January 22. American Life League urges all who are concerned about the safety of American women and babies to contact the FDA Commissioner, Lester M. Crawford, urging him not to reverse the 2004 decision rejecting over-the-counter status for this deadly drug. You may contact Mr. Crawford at 301-827-2410 or .
Release issued: 13 Jan 05